半乳糖凝集素-3与心力衰竭的研究进展

摘要/Abstract

关键词: 半乳糖凝集素-3, 心力衰竭, 心室重构, 预后, 生物标志物

中图分类号:

R541.6

孙宏超, 金凤表, 侯维娜, 李博, 侯瑞田. 半乳糖凝集素-3与心力衰竭的研究进展[J]. 承德医学院学报, 2017, 34(2): 151-154.

[1] Ho JE,Liu C,Lyass A,et al.Galectin-3,a marker of cardiac firosis,predicts incident heart failure in the community[J].J Am Coll Cardiol, 2012,60(14):1249-1256.
[2] Sharma K,Kass DA.Heart failure with preserved ejection fraction:mechanisms,clinical features,and therapies[J].Circ Res,2014,115(1):79-96.
[3] Coburn E,Frishman W.Comprehensive review of the prognostic value of galectin-3 in heart failure[J].Cardiol Rev,2014,22(4):171-175.
[4] Hrynchyshyn N,Jourdain P,Desnos M,et al.Galectin-3:a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure[J].Arch Cardiovasc Dis,2013,106(10):541-546.
[5] Rabinovich GA,Liu FT,Hirashima M,et al.An emerging role for galectins in tuning the immune response:lessons from experimental models of inflmmatory disease,autoimmunity and cancer[J]. Scand J Immunol,2007,66(2-3):143-158.
[6] Viguier M,Advedissian T,Delacour D,et al.Galectins in epithelial functions[J].Tissue Barriers,2014,6(2):e29103.
[7] Liu FT,Patterson RJ,Wang JL.Intracellular functions of galectins[J].Biochim Biophys Acta, 2002,1572(2-3):263-273.
[8] Funasaka T,Raz A,Nangia-Makker P.Galectin-3 in angiogenesis and metastasis[J].Glycobiology, 2014,24(10):886-891.
[9] Fortuna-Costa A,Gomes AM,Kozlowski EO,et al.Extracellular galectin-3 in tumor progression and metastasis[J].Front Oncol,2014, 4(16):138.
[10] Jiang JX,Chen X,Hsu DK,et al.Galectin-3 modulates phagocytosis-induced stellate cell activation and liver firosis in vivo[J]. Am J Physiol Gastrointest Liver Physiol,2012,302(4): 439-446.
[11] Lok DJ,Van Der Meer P,de la Porte PW,et al.Prognostic value of galectin-3,a novel marker of firosis, in patients with chronic heart failure:data from the DEAL-HF study[J].Clin Res Cardiol,2010,99(5):323-328.
[12] de Boer RA,Voors AA,Muntendam P,et al.Galectin-3:a novel mediator of heart failure development and progression[J].Eur J Heart Fail,2009,11(9):811-817.
[13] Morrow DA, O’Donoghue ML. Galectin-3 in cardiovascular disease: a possible window into early myocardial firosis[J].J Am Coll Cardiol,2012,60(14):1257-1258.
[14] Sharma UC,Pokharel S,van Brakel TJ,et al.Galectin-3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation, 2004,110(19):3121-3128.
[15] Bayes-Genis A,de Antonio M,Vila J,et al.Head-to-head comparison of 2 myocardial firosis biomarkers for long-term heart failure risk stratifiation:ST2 versus galectin-3[J].J Am Coll Cardiol,2014,63(2):158-166.
[16] Lin YH,Lin LY,Wu YW,et al.The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients[J].Clin Chim Acta,2009, 409(1-2):96-99.
[17] de Boer RA,Lok DJ,Jaarsma T,et al.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction[J].Ann Med,2011,43(1):60-68.
[18] Lakomkin SV,Skvortsov AA,Goriunova TV,et al.Galectin 3-a new biomarker for diagnostics and outcome of chronic heart failure[J].Kardiologiia,2012,52(3):45-52.
[19] Liu,D’Ambrosio M,Liao TD,et al.N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin[J].Am J Physiol Heart Circ Physiol,2009,296(2):404-412.
[20] Yu L,Ruifork W,Meissner M,et al.Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J].Circ Heart Fail,2013,6(12):107-117.
[21] Milting H,Ellinghaus P,Seewald M,et al.Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechannical circulatory support devices[J].J Heart Lung Transplant,2008,27(6):589-596.
[22] Breyley JG,Novak E,Wittenberg AM,et al.Soluble ST2 is associated with increased mortality and reclassifis risk in patients with severe aortic stenosis[J].J Am Coll Cardiol,2014, 63(1):1920.
[23] Chen K,Jiang RJ,Wang CQ,et al.Predictive value of plasma galectin-3 in patients with chronic heart failure[J].Eur Rev Med Pharmacol Sci,2013,17(8):1005-1011.
[24] van Kimmenade RR,Januzzi JL Jr,Ellinor PT,et al.Utility of amino-terminal pro-brain natriuretic peptide,galectin-3,and apelin for the evaluation of patients with acute heart failure[J].J Am Coll Cardiol,2006,48(6):1217-1224.
[25] Calvier L,Miana M,Reboul P,et al.Galectin-3 mediates aldosterone-induced vascular firosis[J].Arterioscler Thromb Vasc Biol,2013,33(1):67-75.

半乳糖凝集素-3与心力衰竭的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	严汀华, 谢雪华, 江金华, 吴炜. NLR在乙肝相关慢加急性肝衰竭诊断及预后预测价值[J]. 承德医学院学报, 2021, 38(5): 379-382.
[2]	麻新国, 王卫清, 吴森林, 乔丽. 厄贝沙坦氢氯噻嗪联合注射用硝普钠治疗急性心衰的临床观察[J]. 承德医学院学报, 2021, 38(4): 298-300.
[3]	李雪峰, 王清芳, 冯玉凤. Lp-PLA2、Annexin A2与溶栓后急性缺血性脑卒中患者预后的相关性[J]. 承德医学院学报, 2021, 38(4): 301-305.
[4]	曾宪任. 优化急诊护理流程对急性心肌梗死患者救治效果的分析[J]. 承德医学院学报, 2021, 38(4): 317-319.
[5]	张春娥. 家庭护理模式对老年慢性心衰患者的影响[J]. 承德医学院学报, 2021, 38(4): 323-326.
[6]	王丹丹, 巨士文. 子宫内膜异位症患者VEGF、MMP-9、tPA水平与预后关系分析[J]. 承德医学院学报, 2021, 38(3): 191-194.
[7]	王丽娟, 刘燕. miR-708在儿童急性淋巴细胞白血病中的诊断及预后[J]. 承德医学院学报, 2021, 38(1): 1-5.
[8]	卓艳霞, 孙明昌, 张永卓. 儿童急性淋巴细胞白血病中miR-326的表达及临床意义[J]. 承德医学院学报, 2021, 38(1): 9-12.
[9]	戴允楠, 殷玉明, 李青山. 血常规参数与妇科恶性肿瘤预后关系的研究进展[J]. 承德医学院学报, 2020, 37(6): 512-515.
[10]	何孝敏. 原发性肝癌患者TSGF、GP73水平与预后关系的研究[J]. 承德医学院学报, 2020, 37(5): 374-377.
[11]	张莉. 急性ST段抬高型心肌梗死患者可溶性致癌抑制因子2水平与预后的相关性[J]. 承德医学院学报, 2020, 37(4): 296-298.
[12]	魏恒争. 冠脉慢性完全闭塞病变闭塞支数对心肌功能及心室重构的影响[J]. 承德医学院学报, 2020, 37(1): 15-17.
[13]	邝静. 俯卧位通气护理对严重创伤后ARDS患者预后的影响[J]. 承德医学院学报, 2020, 37(1): 52-53.
[14]	陈新立. 重组人脑利钠肽联合硝普钠和多巴胺治疗难治性心力衰竭45例[J]. 承德医学院学报, 2019, 36(6): 468-471.
[15]	张永敏. 血清sST2、IL-33水平在CRF患者心功能不全诊断中的临床价值^*[J]. 承德医学院学报, 2019, 36(6): 509-511.